赫尔格
DNA旋转酶
化学
体内
拓扑异构酶
拓扑异构酶
药理学
拓扑异构酶抑制剂
效力
抗生素
体外
铅化合物
生物化学
大肠杆菌
生物
钾通道
生物物理学
基因
生物技术
作者
Yanran Lu,Sandip Vibhute,Linsen Li,Antony A. Okumu,Steven C. Ratigan,Sheri Nolan,Jonathan L. Papa,Chelsea A. Mann,Anthony E. English,Anna Chen,Justin T. Seffernick,Bryan Koci,Leonard R Duncan,Brieanna Roth,Jason E. Cummings,Richard A. Slayden,Steffen Lindert,Craig A. McElroy,Daniel J. Wozniak,Jack C. Yalowich,Mark J. Mitton‐Fry
标识
DOI:10.1021/acs.jmedchem.1c01250
摘要
Novel bacterial topoisomerase inhibitors (NBTIs) are among the most promising new antibiotics in preclinical/clinical development. We previously reported dioxane-linked NBTIs with potent antistaphylococcal activity and reduced hERG inhibition, a key safety liability. Herein, polarity-focused optimization enabled the delineation of clear structure-property relationships for both microsomal metabolic stability and hERG inhibition, resulting in the identification of lead compound 79. This molecule demonstrates potent antibacterial activity against diverse Gram-positive pathogens, inhibition of both DNA gyrase and topoisomerase IV, a low frequency of resistance, a favorable in vitro cardiovascular safety profile, and in vivo efficacy in a murine model of methicillin-resistant Staphylococcus aureus infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI